Robin Zon

BRE06-109

A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group Study BRE06-109
Status
Closed
Cancer Types
Breast
Locations